Textbook of Personalized Medicine - Second Edition [2015]

690 Cost-Effectiveness of Warfarin Pharmacogenomics Review of studies incorporating clinical effi cacy data of genotype-guided d ...

691 Lowering the High Costs of Cancer Chemotherapy Pharmacogenomics for cancer is being driven by the fact that treatment costs ...

692 At point-of-care, the case studies personalized medicine will need to measure outcomes, which are important for policy-maker ...

K.K. Jain, Textbook of Personalized Medicine, DOI 10.1007/978-1-4939-2553-7_24, 693 © Springer Science+Business Media New York 2 ...

694 stringent evidence requirements can address the high rate of incidental fi ndings. To that end the team developed a peer pro ...

695 in scientifi c journals. The policy also asks that recipients of GWAS data acknowledge the submitting investigator in any pu ...

696 generated 3.8 terabases of data. In 2009, the project is expected to up that dramati- cally, producing a petabyte of data. B ...

697 Translation of Genomic Research into Genetic Testing for Healthcare Advances in genomics have led to mounting expectations i ...

698 Long-Term Behavioral Effects of Personal Genetic Testing In 2008, Scripps Translational Science Institute (STSI), Navigenics ...

699 Connected Health and Personalized Medicine The term ‘connected health (CH)’ has been increasingly used in recent years to de ...

700 Collaboration Between the Industry and the Academia The industry has taken an initiative in developing personalized medicine ...

701 Opportunities and Challenges of Personalized Medicine Prospects and Limitations of Genetic Testing Genotyping will be for tw ...

702 diseases and conditions as was anticipated, and suggestion has been made to turn more sharply toward the study of rare varia ...

703 high genetic risk and better quantifi cation of risk in family members. Greatest progress will be made in understanding the ...

704 (absorption, distribution, metabolism, and excretion) could be incorporated into this system. Progress in nanomedicine with ...

705 Marked increase in the number of validated biomarkers and their use for monitoring therapy. Most of the ethical and policy ...

706 Concluding Remarks About the Future of Personalized Medicine In the year 1998, when the fi rst monograph with the title (“Pe ...

707 HGP has provided a common scaffold of sequencing where every gene and con- trol element can now be mapped to its correct si ...

708 to socio-economic factors in some developing Asian countries. Japan, with an advanced healthcare system and a prominent posi ...

K.K. Jain, Textbook of Personalized Medicine, DOI 10.1007/978-1-4939-2553-7, 709 © Springer Science+Business Media New York 2015 ...